Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Who are the long-term responders to immuno and targeted therapy in melanoma?

Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, discusses who the long-term responders are to immunotherapy and targted therapy in melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.